Organogenesis (ORGO) Competitors $4.58 -0.15 (-3.17%) Closing price 04:00 PM EasternExtended Trading$4.58 +0.00 (+0.09%) As of 04:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ORGO vs. IBRX, CNTA, ARWR, BLTE, RXRX, BHC, OCUL, AGIO, DNLI, and IDYAShould you be buying Organogenesis stock or one of its competitors? The main competitors of Organogenesis include ImmunityBio (IBRX), Centessa Pharmaceuticals (CNTA), Arrowhead Pharmaceuticals (ARWR), Belite Bio (BLTE), Recursion Pharmaceuticals (RXRX), Bausch Health Cos (BHC), Ocular Therapeutix (OCUL), Agios Pharmaceuticals (AGIO), Denali Therapeutics (DNLI), and IDEAYA Biosciences (IDYA). These companies are all part of the "pharmaceutical products" industry. Organogenesis vs. Its Competitors ImmunityBio Centessa Pharmaceuticals Arrowhead Pharmaceuticals Belite Bio Recursion Pharmaceuticals Bausch Health Cos Ocular Therapeutix Agios Pharmaceuticals Denali Therapeutics IDEAYA Biosciences Organogenesis (NASDAQ:ORGO) and ImmunityBio (NASDAQ:IBRX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and risk. Do institutionals & insiders have more ownership in ORGO or IBRX? 49.6% of Organogenesis shares are held by institutional investors. Comparatively, 8.6% of ImmunityBio shares are held by institutional investors. 33.0% of Organogenesis shares are held by company insiders. Comparatively, 76.8% of ImmunityBio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has higher valuation & earnings, ORGO or IBRX? Organogenesis has higher revenue and earnings than ImmunityBio. Organogenesis is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOrganogenesis$482.04M1.21$860K-$0.14-32.71ImmunityBio$14.74M155.83-$413.56M-$0.48-5.06 Is ORGO or IBRX more profitable? Organogenesis has a net margin of -1.92% compared to ImmunityBio's net margin of -648.57%. ImmunityBio's return on equity of 0.00% beat Organogenesis' return on equity.Company Net Margins Return on Equity Return on Assets Organogenesis-1.92% -0.37% -0.20% ImmunityBio -648.57%N/A -113.86% Does the media prefer ORGO or IBRX? In the previous week, ImmunityBio had 13 more articles in the media than Organogenesis. MarketBeat recorded 16 mentions for ImmunityBio and 3 mentions for Organogenesis. Organogenesis' average media sentiment score of 0.68 beat ImmunityBio's score of 0.57 indicating that Organogenesis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organogenesis 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ImmunityBio 4 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend ORGO or IBRX? Organogenesis currently has a consensus price target of $7.50, suggesting a potential upside of 63.76%. ImmunityBio has a consensus price target of $10.75, suggesting a potential upside of 342.39%. Given ImmunityBio's stronger consensus rating and higher probable upside, analysts clearly believe ImmunityBio is more favorable than Organogenesis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Organogenesis 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67ImmunityBio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Which has more volatility and risk, ORGO or IBRX? Organogenesis has a beta of 1.76, meaning that its share price is 76% more volatile than the S&P 500. Comparatively, ImmunityBio has a beta of 0.12, meaning that its share price is 88% less volatile than the S&P 500. SummaryImmunityBio beats Organogenesis on 9 of the 17 factors compared between the two stocks. Get Organogenesis News Delivered to You Automatically Sign up to receive the latest news and ratings for ORGO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ORGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORGO vs. The Competition Export to ExcelMetricOrganogenesisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$581.02M$2.48B$5.70B$9.79BDividend YieldN/A1.68%3.77%4.10%P/E Ratio-32.7121.6430.8625.25Price / Sales1.21545.59403.9088.50Price / Cash22.6725.4525.2228.45Price / Book2.195.559.516.00Net Income$860K$31.83M$3.26B$265.34M7 Day Performance-0.65%4.99%4.49%2.81%1 Month Performance4.81%4.04%5.18%1.50%1 Year Performance78.91%11.07%31.98%25.46% Organogenesis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORGOOrganogenesis4.2426 of 5 stars$4.58-3.2%$7.50+63.8%+84.8%$581.02M$482.04M-32.71950IBRXImmunityBio2.2592 of 5 stars$2.47+1.2%$12.25+396.0%-36.4%$2.31B$14.74M-5.15590CNTACentessa Pharmaceuticals2.1848 of 5 stars$16.61-2.4%$28.10+69.2%+44.4%$2.27B$6.85M-9.18200News CoverageEarnings ReportAnalyst DowngradeInsider TradeAnalyst RevisionARWRArrowhead Pharmaceuticals4.2049 of 5 stars$17.21+4.8%$43.14+150.7%-9.6%$2.27B$3.55M-13.45400News CoverageInsider TradeAnalyst RevisionBLTEBelite Bio2.5454 of 5 stars$69.50-0.5%$96.67+39.1%+33.4%$2.22BN/A-51.1010Earnings ReportRXRXRecursion Pharmaceuticals2.1378 of 5 stars$5.29-1.3%$7.00+32.3%-14.4%$2.18B$58.84M-2.97400BHCBausch Health Cos4.3075 of 5 stars$6.68+16.1%$9.00+34.8%+45.5%$2.13B$9.63B25.6820,700Positive NewsOptions VolumeHigh Trading VolumeOCULOcular Therapeutix3.8899 of 5 stars$12.56+2.9%$17.20+36.9%+55.6%$2.12B$63.72M-9.81230AGIOAgios Pharmaceuticals4.281 of 5 stars$35.10-1.8%$56.33+60.5%-17.8%$2.08B$36.50M3.19390DNLIDenali Therapeutics4.141 of 5 stars$13.91-0.3%$33.85+143.3%-36.1%$2.03B$330.53M-5.21430Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionIDYAIDEAYA Biosciences4.4636 of 5 stars$22.84-1.1%$48.09+110.6%-35.6%$2.02B$7M-6.0380 Related Companies and Tools Related Companies ImmunityBio Alternatives Centessa Pharmaceuticals Alternatives Arrowhead Pharmaceuticals Alternatives Belite Bio Alternatives Recursion Pharmaceuticals Alternatives Bausch Health Cos Alternatives Ocular Therapeutix Alternatives Agios Pharmaceuticals Alternatives Denali Therapeutics Alternatives IDEAYA Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ORGO) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersBiotech Alert: With news on MPox, RSV, and more, this tiny firm could disrupt a $3B marketA small biotech is stepping into the spotlight with a first-in-class antiviral platform—and it could be one of...Smallcaps Daily | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Organogenesis Please log in to your account or sign up in order to add this asset to your watchlist. Share Organogenesis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access